The role of gonadotropin releasing hormone in normal and pathologic endocrine processes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 14, Issue 4, 2007, Pages 306-310

  Rothman, Micol S ^a   Wierman, Margaret E ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Fibroblast growth factor receptor 1; G protein coupled receptor 54; Gonadotropin releasing hormone; Kisspeptin; Ovulation induction; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; ESTRADIOL; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FOLLITROPIN; G PROTEIN COUPLED RECEPTOR 54; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; KISSPEPTIN; KISSPEPTIN 10; LEUPRORELIN; LUTEINIZING HORMONE; TESTOSTERONE;

BODY COMPOSITION; CELL MIGRATION; CLINICAL STUDY; CLINICAL TRIAL; COST; DRUG INTERMITTENT THERAPY; ENDOMETRIOSIS; GENE MUTATION; GYNECOMASTIA; HISTAMINE RELEASE; HORMONE RELEASE; HOT FLUSH; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; INFERTILITY; INTRAABDOMINAL FAT; LIBIDO DISORDER; LONG TERM CARE; METABOLIC SYNDROME X; METABOLISM; NEGATIVE FEEDBACK; NERVE CELL DIFFERENTIATION; NONHUMAN; OBESITY; OVULATION INDUCTION; POSITIVE FEEDBACK; PROSTATE CANCER; PROTEIN ANALYSIS; PUBERTY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE;

ENDOCRINE GLANDS; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYPOTHALAMUS; INFERTILITY; MALE; PROSTATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 34447564990     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3281e2c9fc     Document Type: Review

References (40)

1. Wierman ME, Pawlowski JE, Allen MP, et al. Molecular mechanisms of gonadotropin-releasing hormone neuronal migration. Trends Endocrinol Metab 2004; 15:96-102.
2. Tobet SA, Schwarting GA. Minireview: recent progress in gonadotropin-releasing hormone neuronal migration. Endocrinology 2006; 147:1159-1165. Discusses known and potential candidates for GnRH neuronal migratory defects to result in disruption of the normal ontogeny of the reproductive axis.
3. Boepple PA, Mansfield MJ, Wierman ME, et al. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev 1986; 7:24-33.
4. Harrison GS, Wierman ME, Nett TM, et al. Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocr Relat Cancer 2004; 11:725-748.
5. Waldstreicher J, et al. The genetic and clinical heterogeneity of gonadotropin-releasing hormone deficiency in the human. J Clin Endocrinol Metab 1996; 81:4388-4395.
6. Karges B, De Roux N. Molecular genetics of isolated hypogonadotropic hypogonadism and Kallmann syndrome. Endocr Dev 2005; 8:67-80.
7. Seminara SB. Mechanisms of disease: the first kiss - a crucial role for kisspeptin-1 and its receptor, G-protein-coupled receptor 54, in puberty and reproduction. Nat Clin Pract Endocrinol Metab 2006; 2:328-334. An excellent, concise review of the discovery of GPR54, and the cellular and human studies that have followed.
8. Schwanzel-Fukuda M, Bick D, Pfaff DW. Luteinizing hormone-releasing hormone (LHRH)-expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome. Brain Res Mol Brain Res 1989; 6:311-326.
9. MacColl G, Quinton R, Bouloux PM. GnRH neuronal development: insights into hypogonadotrophic hypogonadism. Trends Endocrinol Metab 2002; 13:112-118.
10. Pitteloud N, Meysing A, Quinton R, et al. Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol Cell Endocrinol 2006; 254-255:60-69. Paper demonstrating that FGFR-1 mutations can have a wide range of phenotypes, as opposed to the uniformly severe hypogonadism seen in patients with Kal1 mutations.
11. Gill JC, Tsai PS. Expression of a dominant negative FGF receptor in developing GNRH1 neurons disrupts axon outgrowth and targeting to the median eminence. Biol Reprod 2006; 74:463-472.
12. Pitteloud N, Quinton R, Pearce SHS, et al. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest 2007; 117:457-463. First report of patients with heterozygous mutations in more than one protein to result in IHH.
13. Dungan HM, Clifton DK, Steiner RA. Minireview: kisspeptin neurons as central processors in the regulation of gonadotropin-releasing hormone secretion. Endocrinology 2006; 147:1154-1158.
14. Ohtaki T, Shintani Y, Honda S, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 2001; 411:613-617.
15. Muir AI, Chamberlainb L, Elshourbagyc NA, et al. AXOR-12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. J Biol Chem 2001; 276:28969-28975.
16. Lee JH, Welch DR. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 1997; 57:2384-2387.
17. De Roux N, Genin E, Carel J-C, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A 2003; 100:10972-10976.
18. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med 2003; 349:1614-1627.
19. Navarro VM, Castellano JM, Fernandez-Fernandez R, et al. Characterization of the potent luteinizing hormone-releasing activity of KiSS-1 peptide, the natural ligand of GPR54. Endocrinology 2005; 146:156-163.
20. Shahab M, Mastronardi C, Seminara SB, et al. Increased hypothalamic GPR54 signaling: a potential mechanism for initiation of puberty in primates. Proc Natl Acad Sci U S A 2005; 102:2129-2134.
21. Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab 2005; 90:6609-6615.
22. Plant TM, Ramaswamy S, Dipietro MJ. Repetitive activation of hypothalamic G protein-coupled receptor 54 with intravenous pulses of kisspeptin in the juvenile monkey (Macaca mulatta) elicits a sustained train of gonadotropin-releasing hormone discharges. Endocrinology 2006; 147:1007-1013. Administration of kisspeptin-10 to juvenile monkeys started GnRH pulses prematurely. Treatment with a GnRH antagonist abolished thus release. This paper showed that increased expression of hypothalamic Kiss-1 activating GPR54 is critical in modulating the changes in GnRH pulsation across puberty.
23. Roa J, Vigo E, Castellano JM, et al. Hypothalamic expression of KiSS-1 system and gonadotropin-releasing effects of kisspeptin in different reproductive states of the female rat. Endocrinology 2006; 147:2864-2878.
24. Kauffman AS, Gottsch ML, Roa J, et al. Sexual differentiation of KiSS1 gene expression in the brain of the rat. Endocrinology 2007; 148:1774-1783.
25. Gottsch ML, Clifton DK, Steiner RA. Kisspepeptin-GPR54 signaling in the neuroendocrine reproductive axis. Mol Cell Endocrinol 2006; 254-255:91-96.
26. Han SK, Gottsch ML, Lee KJ, et al. Activation of gonadotropin-releasing hormone neurons by kisspeptin as a neuroendocrine switch for the onset of puberty. J Neurosci 2005; 25:11349-11356.
27. Clarkson J, Herbison AE. Postnatal development of kisspeptin neurons in mouse hypothalamus; sexual dimorphism and projections to gonadotropin-releasing hormone neurons. Endocrinology 2006; 147:5817-5825.
28. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 2006; 27:170-207. A very thorough review of the physiology of ovarian function, the development and current use of agents for ovarian stimulation in in-vitro fertilization protocols and current clinical issues.
29. Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst Rev 2000; 2:CD001299.
30. Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001; 358:1793-1803.
31. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006; 3:CD001750. A comprehensive review of the data on GnRH agonists vs. antagonists for in-vitro fertilization protocols. Twenty-seven randomized clinical trials were included. Pregnancy rates were significantly higher in the agonist group, but the antagonist group had lower rates of ovarian hyperstimulation.
32. Orvieto R, Rabinson J, Meltzer S, et al. GnRH agonist versus GnRH antagonist in ovarian stimulation: is the emperor naked? Clin Exp Obstet Gynecol 2006; 33:197-199.
33. Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A 1982; 79:1658-1662.
34. Engel JB, Schally AV. Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007; 3:157-167.
35. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003; 61 (2 Suppl 1):32-38.
36. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24:3979-3983.
37. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91:1305-1308. This paper assessed the effect of GnRH agonists on insulin sensitivity in men with prostate cancer. An increase in fat mass and a decrease in insulin sensitivity were observed, raising concerns about cardiac risk factors in men treated with androgen deprivation.
38. Smith MR. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res 2007; 13:241-245.
39. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164 (3 Pt 1):726-729.
40. Wright JL, Higano CS, Lin DW. Intermittent androgen deprivation: clinical experience and practical applications. Urol Clin North Am 2006; 33:167-179; vi. Thorough review of rationale, current data and future directions for intermittent androgen deprivation for metastatic prostate cancer.